



SCS  
Swiss Chemical  
Society

## Community News

[www.scg.ch](http://www.scg.ch)

[www.chemanager-online.com](http://www.chemanager-online.com)

### SWISS CHEMICAL SOCIETY NEWS

#### Call for Nominations for the SCS Awards 2018



As one of our four strategic pillars, SCS awards excellence in science and chemistry respectively and is proud of its renowned award program that goes back to the age of 1936 with the ceremony of the first Werner Prizes to Dr. T. Posternak, Genève, and Prof. G. Schwarzenbach, Zürich.

The society hereby calls for nominations for the 2018 SCS Awards. Nominations have to be submitted electronically to [info@scg.ch](mailto:info@scg.ch). The deadline for all documents to reach the Swiss Chemical Society is September 30, 2017.

For specific award information and required documents please visit our website <http://scg.ch/awards>

#### Paracelsus Prize

CHF 20'000 and medal in gold

The Paracelsus Prize is awarded to an internationally outstanding scientist for his or her lifetime achievements in chemical research. It is awarded every two years.

#### Werner Prize

CHF 10'000 and medal in bronze

The Werner Prize is awarded to a promising young Swiss scientist or scientist working in Switzerland for outstanding independent chemical research. At the time of the nomination deadline the candidate ought not to be older than 40 years and may not be a tenured professor or someone holding a managerial position in industry. The prize is awarded annually.

#### Balmer Prize

CHF 2'000 for individuals and CHF 2'000 for the school's chemistry department or CHF 3'000 for a group and CHF 1'000 for the school's chemistry department and medal in bronze.

The Balmer Prize is awarded to a teacher working in Switzerland at high school (gymnasium) level for innovation in chemistry teaching. The innovation must be easily applicable in current teaching and the costs for materials must be modest. The candidate may not make any claim to copyright in the innovation. The prize is awarded annually.

#### Dr. Max Lüthi Award

CHF 1'000 and medal in bronze

The Dr. Max Lüthi Award is presented for an outstanding diploma thesis in Chemistry conducted at a Swiss University of Applied Sciences. Nominations must be submitted by the head of the Chemistry Department of a Swiss University of Applied Sciences. The prize is awarded annually.

#### Sandmeyer Award

CHF 10'000 for individuals or CHF 20'000 for groups

The Sandmeyer Prize is awarded to a person – excluding tenured professors – or to a group for outstanding work in industrial or applied chemistry. The work must be completed in Switzerland or with the involvement of a Swiss national. The prize is awarded annually and supported by the Division of Industrial and Applied Chemistry of the SCS.

#### SISF/SCS Industrial Science Awards

The SISF/SCS Industrial Scientific Awards are given to scientists working in Switzerland that are still working in industrial R&D.

#### Industrial Investigator Award

Certificate and cash check of CHF 7'000

The award honors successful investigators with outstanding achievements.

#### Senior Industrial Investigator Award

Certificate and cash check of CHF 10'000

The award honors very successful and established investigators with outstanding achievements over many years.

#### Distinguished Industrial Investigator Award

Certificate and cash check of CHF 15'000

Rewarded only on decision by the board

The award honors senior scientists at the top of their research career for their lifetime achievements.

SCS Awards are sponsored and supported by the SISF:



#### Renaming of KGF to Swiss Industrial Science Fond (SISF)



At its meeting in early June 2017, the board of the former Kontaktgruppe für Forschungsfragen (KGF) decided to rename the organization to a more generic and more self-explanatory name. With immediate effect, the organization is called Swiss Industrial Science Fund (SISF).

The SISF promotes scientific excellence in research and education in Switzerland, within the scope of its member companies.

The SISF is an unregistered partnership of the member companies (in alphabetic order): BASF, Novartis, Roche and Syngenta.

Each member is represented through one or two delegates. They meet quarterly to discuss and decide on applications for support.

<http://sisf.info>

## Hans Peter Lüthi, ETH Zurich, elected as Executive Board Member of scienceindustries



At its general assembly at Siegfried AG, Zofingen, on May 19, 2017, the delegates of scienceindustries elected PD Dr. Hans Peter Lüthi from ETH Zurich as new member of the executive board. Hans Peter Lüthi succeeds Prof. Christoph Copéret as SCS delegate and will be part of the the “Vorstandsausschuss Bildung und Forschung VABF”.

### About scienceindustries

scienceindustries is the Swiss business association for the chemical, pharmaceutical and biotech industries. More than 250 companies within the chemical, pharmaceutical, biotech and other science-based industries operating in Switzerland are members. scienceindustries is a significant member of economiesuisse, the umbrella organization of the Swiss economy.

<https://en.scienceindustries.ch>

## Prof. Edwin Constable, University of Basel, elected as Titular Member of IUPAC



Prof. Ed Constable will support the IUPAC Division VIII, Chemical Nomenclature and Structure Representation, as one of ten titular members.

The Division has an advisory subcommittee of about 40 people, charged with advising the Division Committee on the needs of the community, and developing project proposals.

In his new role Ed Constable, who is working for IUPAC for many years, will focus on a clear and unambiguous nomenclature with high acceptance in the chemical community. Furthermore he will represent the interests of supramolecular chemistry and push the classification of nano particles.

Source: [www.unibas.ch](http://www.unibas.ch)

## A Warm Welcome to Our New Members!



Period: 31.05.2017 – 10.07.2017

Sadig Aghazada, Sion - Fabian Belleflamme, Zürich - Andreas Boudier, Zürich - Tobias Burger, Wädenswil - Daniel Cavlovic, Basel - Dalu Chang, Geneva - Yixing Chen, Lausanne - Cheng Yi Chen, Stetten - Borte Emiroglu, Zürich - Behnaz Ghaffari, Zürich - Jilali Kessabi, Rheinfelden - Xudong Kong, Lausanne - Philipp Krastel, Grenzach-Wyhlen - Ulrich Lorenz, Lausanne - Halil Okur, Lausanne - Ophélie Planes, Lausanne - Irina Ritsch, Zürich - Stefan Ruider, Geneva - Wei Shu, Zürich - Nikolay Smolentsev, Renens - Thomas Vonderach, Zürich

## HONORS AND AWARDS

### Prof. em. Martin Quack, ETH Zurich, elected Foreign Honorary Member of the AAAS



*Prof. em. Martin Quack* was newly elected Foreign Honorary Member by the American Academy of Arts and Sciences.

The AAAS encompasses over 4,600 Fellows and 600 Foreign Honorary Members reflecting the full range of disciplines and professions: mathematics, the physical and biological sciences, medicine, the social sciences and humanities, business, government, public affairs, and the arts. Among the Academy's Fellows are more than 250 Nobel laureates and 60 Pulitzer Prize winners.

Source: [www.chab.ethz.ch](http://www.chab.ethz.ch)

# expression CMS

The first mass spectrometer designed for chemists



Direct mass analysis of solid and liquid samples



Direct mass analysis from TLC-plates

Reaction Monitoring & Compound ID in 30 seconds

**Advion**

For more information:

[central-europe@advion.com](mailto:central-europe@advion.com) | [www.expressioncms.com](http://www.expressioncms.com)

### Prof. Roger Alberto, University of Zurich, wins Humboldt Research Award



The Humboldt research award is given to persons, which are recognized internationally as outstandingly qualified academic researchers.

The award is granted in recognition of **Prof. Roger Alberto's** entire achievements to date, for his fundamental discoveries, new theories and his research impact with a high potential to continue

producing cutting-edge achievements in the future.

Award winners are invited to spend a period of up to one year cooperating on a long-term research project with specialist colleagues at a research institution in Germany. The award is valued at €60,000.

[www.humboldt-foundation.de/web/humboldt-award.html](http://www.humboldt-foundation.de/web/humboldt-award.html)

Source: [www.chem.uzh.ch](http://www.chem.uzh.ch)

### Prof. Sereina Riniker, ETH Zurich, receives the OpenEye Outstanding Junior Faculty Award



The American Chemical Society COMP OpenEye Outstanding Junior Faculty Award is given annually for outstanding tenure-track junior faculty members.

**Prof. Sereina Riniker** studied for her PhD at that same institution with Professor Wilfred van Gunsteren, and then spent some time working with Dr Greg Landrum at Novartis in Basel and

the USA before returning to Zürich in 2014. This prize recognises her contributions to the development of the RDKit open source library for chemoinformatics and the GROMOS molecular dynamics program, and her ongoing research work on the applications of molecular dynamics in biomolecular systems.

Source: [www.chab.ethz.ch](http://www.chab.ethz.ch)

### Dr. Loredana Protesescu, ETH Zurich, receives the ETHZ-MaP Award 2017



The Competence Center for Materials and Processes (MaP) awards a prize to the best interdisciplinary PhD thesis of ETH Zurich in the area of Materials and Processes in the preceding year. This year's award goes to **Dr. Loredana Protesescu**, former PhD student in the group of Prof. Kovalenko.

Source: [www.chab.ethz.ch](http://www.chab.ethz.ch)

## JOURNAL NEWS

### 100<sup>th</sup> Anniversary Celebration of Helvetica at the SCS Fall Meeting 2017



The Swiss Chemical Society and Helvetica Chimica Acta (HCA) share a long history, and the 100<sup>th</sup> Anniversary of HCA finds them closer than ever before. To commemorate the remarkable history of HCA and the relaunch of the journal as Helvetica – A Journal of the Swiss Chemical Society, we invited two distinguished speakers with strong connections

to Switzerland to give a lecture at the Fall Meeting 2017. This event will celebrate the spirit of Helvetica: Fantastic science, insightful scholarship, and molecular surprises. It will also serve as a launch pad for its next 100 years!

Mon, 21. August 2017, 13.00–14.20h, University of Bern, Areal von Roll, lecture hall B6.001

**Prof. Harry Anderson**, University of Oxford (website)

«Flow of Energy & Charge in Porphyrin Nanostructures»

**Prof. Luisa De Cola**, Université de Strasbourg (website)

«Supramolecular and Biomaterial Chemistry»

### Celebrating a Great Milestone: 750<sup>th</sup> Issue of Chemistry – A European Journal I



Issue 33/2017 marks the 750<sup>th</sup> issue of Chemistry – A European Journal. The journal has played a significant role in changing chemistry. Its history has featured top papers from top authors for more than 20 years. Read the Editorial by Neville Compton, which looks back at the journal's history and some of the landmarks along the way. Thanks to all

authors and readers and we look forward to highlighting great chemistry for many more issues to come!

[http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)1521-3765](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-3765)

### Neville Compton to Succeed Peter Göllitz as Editor-in-Chief of Angewandte Chemie



The German Chemical Society (GDCh) and Wiley-VCH would like to announce that Dr. Neville Compton will take over as Editor-in-Chief of Angewandte Chemie from October 1, 2017. Angewandte Chemie, the flagship journal of the GDCh, is a weekly publication steeped in tradition; the German edition is in its 129<sup>th</sup> volume, and the International Edition in its 56<sup>th</sup>.

The journal publishes articles from all fields of chemistry and related disciplines. In 2016 almost 2700 communications and ca. 150 reviews were published; in addition the journal has a vibrant magazine section. All these features combine to make Angewandte Chemie a worldwide leading scientific journal – not only in chemistry.

[http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)1521-3757](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-3757)

## INDUSTRIAL NEWS

Source: [www.chemanager-online.com](http://www.chemanager-online.com)

### Novartis in Pakistan Drug Program

26.05.2017 - Novartis has signed a Memorandum of Understanding (MoU) with Pakistan's Ministry of National Health Services, Regulations and Coordination to increase access to treatment for poor people suffering from chronic diseases.

Under the MoU, Novartis and the ministry will collaborate to deliver a program called Novartis Access. This program will ensure access to high-quality medicines in the public sector, primarily targeting four key non-communicable diseases: cardiovascular diseases; diabetes; respiratory illnesses; and breast cancer. These illnesses are said to be responsible for nearly one-fifth of deaths in people aged between 30 and 70 in Pakistan every year. In a pilot phase, Novartis Access drugs will be made available free-of-charge through selected empanelled hospitals in Islamabad under the Prime Minister's National Health Program. Work has already started to extend the initiative to all districts in the National Health Program. National Health Services Regulations and Coordination minister, Saira Afzal Tarar, said Pakistan is grievously affected by the growth of non-communicable diseases and having access to high-quality treatment at low cost is a critical part of its work to lessen the impact of chronic illnesses in the country.

### UK Leads European Biotech Funding

01.06.17 – A new report released by the UK BioIndustry Association (BIA) showed that the UK received the highest amount of biotech funding compared to anywhere else in Europe last year, and its pipeline for future drug development was the strongest in the region.

Despite Brexit and the US presidential election having a cooling effect on global markets during 2016, the sector still saw robust investment from venture capital funds, with many companies also returning for follow-on funding on the Alternative Investment Market (AIM) as well as seven IPOs taking place for UK-listed companies. The report – Building something great: UK's Global Bioscience Cluster 2016 – revealed that UK companies received £680 million in venture capital, which was more than a third of the total raised in Europe. The country still lagged behind the US biotech clusters of San Francisco and Massachusetts, but was ahead of San Diego. There was also a rise in seed funding to £14 million, up from £11 million in 2015, which BIA said boded well for the future.

The combined venture capital of the UK and Switzerland has now reached 55% of the European total, which would mean that more than half of European venture capital would be deployed outside the EU post-Brexit, if the current trend is maintained. The number of biotech financings through AIM rose from 130 (including eight IPOs) in 2015 to 175 (including seven IPOs) in 2016. In addition, the number of drug products in clinical development (or in registration with regulators) was higher in the UK than anywhere else in Europe. The association said the findings illustrated that the UK is better placed to realize the value of its science base as companies own their technology for longer, which means that they are able to scale up. BIA CEO, Steve Bates, said the UK continues to build towards becoming the third global biotech cluster thanks to its excellent science and great management teams that have the capability to tackle the challenges of working in a global environment.

### Genentech Returns Cancer Drug Rights to NewLink

June 16, 2017: US biotechnology group Genentech, part of Roche, is handing back rights to NewLink Genetics' IDO in-


hibitor GDC-0919 (navoximod), an investigational cancer treatment.

Genentech gained rights to navoximod, which is designed to harness multiple parts of the immune system to fight cancer, in October 2014 as part of a partnership on solid tumor therapies. The deal had an upfront payment of \$150 million and could have been worth more than \$1 billion, including milestones, for NewLink. As a consequence of Genentech's decision, NewLink will pay the US company a low single-digit royalty on any sales of GDC-0919 if it decides to develop and commercialize the drug. Genentech will continue to supply the drug for one year after the agreement's termination. The end of the collaboration also came about a week after NewLink admitted that a Phase II trial of indoximod plus taxane chemotherapy for breast cancer had failed to meet its primary endpoints. The company said it would present full results at an (unspecified) upcoming academic meeting.

However, NewLink's CEO, Charles Link, said: "We remain committed to advancing our IDO pathway inhibitor indoximod, which continues to generate exciting data in combination with anti-PD-1 agents, cancer vaccines, and chemotherapy in multiple cancer types including melanoma, prostate cancer, acute myeloid leukaemia, and pancreatic cancer." NewLink confirmed that its research collaboration with Genentech for the discovery of next generation IDO/TDO (tryptophan 2,3-dioxygenase) inhibitors continues.



## Solvias ligands – explore the scope of catalysis



Reaction 1:  $R-CH_2-CHO + NH_3 \xrightarrow{Rh(cod)_2SbF_6 (5 \text{ mol}\%), \text{ligand} (5 \text{ mol}\%), t\text{-AmOH}, 80^\circ\text{C}, 6 \text{ h}}$

Reaction 2:  $R-CH_2-CHO + NH_3 \text{ or } R'NH_2 \xrightarrow{NaOtBu (1.5 - 4.5 \text{ equiv}), 80 - 100^\circ\text{C}, 7-12 \text{ h}}$

Reaction 3:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 4:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 5:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 6:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 7:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 8:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 9:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 10:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 11:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 12:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 13:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 14:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 15:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 16:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 17:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 18:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 19:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 20:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 21:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 22:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 23:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 24:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 25:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 26:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 27:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 28:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 29:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 30:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 31:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 32:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 33:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 34:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 35:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 36:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 37:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 38:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 39:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 40:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 41:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 42:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 43:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 44:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 45:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 46:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 47:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 48:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 49:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 50:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 51:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 52:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 53:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 54:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 55:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 56:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 57:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 58:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 59:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 60:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 61:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 62:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 63:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 64:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 65:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 66:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 67:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 68:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 69:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 70:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 71:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 72:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 73:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 74:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 75:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 76:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 77:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 78:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 79:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 80:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 81:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 82:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 83:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 84:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 85:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 86:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 87:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 88:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 89:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 90:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 91:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 92:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 93:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 94:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 95:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 96:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 97:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 98:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 99:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 100:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 101:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 102:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 103:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 104:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 105:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 106:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 107:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 108:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 109:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 110:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 111:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 112:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 113:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 114:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 115:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 116:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 117:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 118:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 119:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 120:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 121:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 122:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 123:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 124:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 125:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 126:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 127:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 128:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 129:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 130:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 131:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 132:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 133:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 134:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 135:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 136:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 137:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 138:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 139:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W001-1, S/C 5000, 20 \text{ bar}, 25^\circ\text{C}, 15 \text{ h}}$

Reaction 140:  $R-CH_2-CHO \xrightarrow{[Rh(NBD)]_2, SL-W00$

## Syngenta Eyes Seeds Assets, ChemChina May Float

June 29, 2017; To build up its seeds business, Swiss agrochemicals major, recently acquired by ChemChina, is eager to pick up some of the assets German rival Bayer will be forced to divest in order to gain international regulatory approval for its proposed \$66 billion takeover of industry heavyweight Monsanto.

“We are very interested in seed assets from remedies and beyond that,” CEO Erik Fyrwald said at news conference at Basel headquarters.

In May, Bayer said it was prepared to sell its leading crop protection brand LibertyLink, which includes a herbicide and seeds, allaying the South African Competition Commission’s concerns about competition in the market for GM cotton seeds.

At Syngenta’s annual general meeting in Basel on June 26, the Swiss group and its new owner outlined ambitions and priorities following the completion of the transaction. Syngenta said it aims to profitably grow market share through organic growth and collaborations and is considering targeted acquisitions with a focus on seeds. Here, the goal is to strengthen its leadership position in crop protection and to become an “ambitious number” three in seeds. Figures show that Syngenta is already the third largest global seeds player, but trails some distance behind Monsanto and DuPont. To help close the gap, it plans to pursue its own acquisitions and licensing deals, management said. Key drivers for the next phase of growth will be further expansion in emerging markets, notably China, improvement of its digital presence in the agriculture sector and further investment in new technologies to increase crop yields, while at the same time reducing CO<sub>2</sub> emissions and preserving water resources.

Elected chairman of Syngenta’s board of directors at the meeting, ChemChina Chairman Ren Jianxin confirmed that the Swiss player will retain its operational independence, with the existing management team continuing to run the company. Michel Demaré, former Syngenta chairman and newly elected vice chairman of the now Chinese-owned company, stressed that the group will continue to be headquartered and pay taxes in Switzerland, with major manufacturing and R&D sites remaining in the country.

Seeds will be the main plank of the growth strategy to meet ChemChina’s target for Syngenta to double its revenue over the next five to 10 years, Ren Jianxin said. At the same time, the Chinese chemical producer, which has acquired close to 98% of the group’s shares, announced that it plans to float a minority stake in the medium term to pad its balance sheet.

“The timing of the minority ipo of Syngenta will depend on the market situation, but the time frame would be about five years,” Ren Jianxin, said, while dismissing rumors that the Chinese group could merge with compatriot, state-owned Sinochem.

## Activist Investors Try to Wedge Clariant and Huntsman Apart

July 5, 2017: Activist investors unhappy with the merger plans of Clariant and Huntsman have joined forces to torpedo it.

The Corvex hedge fund of Keith Meister – a protégé of billionaire speculator Carl Icahn – and the 40 North fund of New York real estate investor David Winter with former Bear, Stearns financial analyst David Millstone, announced on July 4 they have acquired a combined 7.2 stake in Clariant that they plan to use as a wedge. Both investment funds have been critical of the prospects for the US-Swiss merger, which was announced in May. A spokesperson for the funds’ acquisition vehicle, White Tale, told international media, “there are excellent opportunities to unlock value from the many high quality businesses that currently comprise Clariant. Unfortunately, we do not believe that the proposed merger with the Huntsman Corporation is one of those options.” White Tale contends that the transaction lacks strategic rationale and undercuts Clariant’s strategy of becoming a pure-play specialty chemicals company. It called on the Basel-based player’s other shareholders “to reject this value destructive merger.” The investors said Clariant would be exchanging almost half its shares for what is primarily a commodity and intermediates business that will further dilute its multiple and create a larger conglomerate discount. In announcing their plans earlier, the Swiss and US chemical producers said the all-stock transaction would create a company with an enterprise value of around \$20 billion, majority owned by Clariant with 52%. CEO-designate of the merged firm, HuntsmanClariant is Huntsman CEO Peter Huntsman, with Clariant CEO Hariolf Kottmann holding the title of chairman.

The two boards of directors have already approved the merger, which they said will create a leading global specialty chemical company with sales of around \$13.2 billion, an adjusted EBITDA of \$2.3 billion and annual cost synergies in excess of \$400 million, to be achieved by reducing operational costs and improving procurement. Some observers saw the power grab by the activists as aimed at triggering a bid for Clariant by an industry bidder that would drive the share price the company funds generally see as a bigger prize than family-owned Huntsman.

Names tossed into the ring included Evonik, Lanxess and BASF. Some of them are said to have expressed interest in Clariant at some time in the past several years. Many analysts reacted to the news saying they regard the Swiss company as the more attractive asset. Some in the past had criticized the fact that the merger partners have too little overlap in their portfolios and no synergies in their manufacturing assets, as this would rob the new company of potential for rationalization moves such as plant

## Keine halben Sachen.



Die Welt ist voll von Halbwissen. Besonders im sensiblen Umfeld der Chemie ist dies jedoch fehl am Platz. Deshalb arbeiten wir seit 1947 mit Leidenschaft und Liebe zum Detail daran, dass evaluierte Daten und Fakten rund um das Themenfeld Chemie zur Verfügung stehen. Immer. Und ohne Ausnahme. So wurde „Der RÖMPP“ Synonym für inzwischen über 65 000 Stichwörter und über 240 000 Querverweise, auf die man sich verlassen kann. Das sollten Sie sich am besten selbst anschauen.

**Sonderkonditionen für SCG-Mitglieder.**

**Nur 100% sind 100%.**  
[www.roempp.com](http://www.roempp.com)

 **Thieme**

closures. At this stage, however, some stressed the plans would be hard to undo.

Clariant had previously acknowledged the increased shareholding by Corvex, adding that it has been in contact with the fund since it initially bought into the company in 2016. "As with all our shareholders, we maintain an open dialog with them," a Clariant spokesman told the news agency Reuters. No date has yet been set for Clariant shareholders to vote on the merger; however, a source told Reuters that a meeting would be scheduled only after Huntsman spins off its titanium dioxide business into a separate firm named Venator, as announced at the beginning of this year. The transaction is targeted to close by the end of 2017, subject to all approvals.

### Merck KGaA and iOnctura in new JV

July 05, 2017; Merck Ventures, the strategic investment arm of German pharmaceuticals and life sciences group Merck KGaA, has created immuno-oncology company iOnctura.

Based in Geneva, Switzerland, the spin-out company was formed around two assets from Merck's Healthcare R&D portfolio and three assets from Cancer Research Technology (CRT), the commercial arm of UK charity Cancer Research. iOnctura aims to develop a pipeline of selected assets targeting and modulating mechanisms that drive immunosuppression in the tumor microenvironment. Immunosuppression has been shown to be one of the main factors behind patients not responding to first-generation checkpoint inhibitors. Through its alliances with Merck and CRT, iOnctura has already built up a pipeline of promising programs and has entered into a research collaboration with CRT Discovery Laboratories. In exchange for the exclusive global option to license three immuno-oncology assets from CRT, iOnctura will give CRT an initial stake in the company and will make further payments on achieving certain milestones as well as royalties on net sales.

The newly formed Swiss company has also secured access to future supplies of avelumab, a fully human monoclonal antibody being developed and commercialized by Merck KGaA together with US drug maker Pfizer, which will enable acceleration into initial clinical proof-of-concept studies. CEO and co-founder of iOnctura, Catherine Pickering, said the company was optimally positioned to explore novel combination therapies and advance them quickly to cancer patients.

Separately, CRT has signed a further deal with Germany's Merck to discover new cancer drugs targeting the Hippo signaling pathway, which regulates cell size and controls tissue growth during development and regeneration. The agreement follows a successful one-year target validation and drug discovery feasibility partnership between CRT's Discovery Laboratories in both London and Cambridge and Merck in Darmstadt, during which time the partners developed a better understanding of the Hippo pathway's role in cancer and how best to drug key targets. Abnormal activation of proteins controlled by this pathway has been linked to the development of a range of cancers, making it an attractive area for the discovery of novel therapies. The partners have now moved into full drug discovery with the aim of eventually identifying molecules to take into preclinical studies and clinical trials.

Under terms of the deal, CRT will receive royalties and milestone payments, which will be invested into the charity's research. Ian Foulkes, CRT's CEO, commented: "We've brought together leading academics in the field and industry to build on world-class research, and we're now focused on developing these early projects for the benefit of cancer patients."



Die Fachhochschule Nordwestschweiz FHNW umfasst neun Hochschulen mit rund 12'000 Studierenden. Die Hochschule für Life Sciences ist international und regional ausgerichtet. Sie generiert Innovationen und Wissen und richtet sich nach gegenwärtigen und zukünftigen Märkten. Am Institut für Chemie und Bioanalytik ist per 01.01.2018 folgende Stelle mit Arbeitsort Muttenz zu besetzen:

## Professor/in (80–100 %) Physikalische Chemie und Prozessmodellierung

**Ihre Aufgaben:** In der Lehre vertreten Sie die Fächer physikalische Chemie, Modellierung und Prozessautomation in unseren Life Sciences-Studiengängen auf der Bachelor- und Masterstufe und setzen dabei moderne didaktische Konzepte im Unterricht ein. Neben der Unterrichtstätigkeit betreuen Sie Praktika, Studierendenprojekte, Bachelor- und Masterarbeiten. Darüber hinaus akquirieren Sie Drittmittel für Forschungs- und Dienstleistungsprojekte und pflegen enge Kontakte zu Industriepartnern und Forschungsinstitutionen. Sie bauen einen Arbeitsschwerpunkt im Bereich der Modellierung, Automatisierung und Digitalisierung chemischer Prozesse auf. In unserem neuen Prozess- und Technologiezentrum entwickeln Sie gemeinsam mit Kollegen neue, integrierte Prozesse für die Life Science-Industrie.

**Ihr Profil:** Sie haben einen Hochschulabschluss in Chemie, Chemie-Ingenieurwesen oder Verfahrenstechnik mit Promotion und verfügen über mehrjährige Industrieerfahrung an der Schnittstelle zwischen synthetischer Chemie und Prozessmodellierung bzw. Verfahrenstechnik, möglichst auch mit fachlicher und personeller Führungsfunktion. Sie haben bereits Erfahrungen in der Automatisierung und Digitalisierung chemischer Prozesse und haben grosses Interesse, in interdisziplinären Teams an künftigen Herausforderungen des digitalen Wandels mitzuarbeiten. Sie verfügen über ein gutes Netzwerk zu Industriepartnern und überzeugen persönlich durch sehr gute Kommunikationsfähigkeit, Ergebnisorientierung und die Fähigkeit, sich und andere zu motivieren. Erfahrungen in der Lehre und Freude am Umgang mit Studierenden sowie Teamgeist und Flexibilität runden Ihr Profil ab.

**Ihre Bewerbung** lassen Sie uns bitte bis zum 15.08.2017 online über die gewünschte Ausschreibung unter [www.fhnw.ch/offene-stellen](http://www.fhnw.ch/offene-stellen), z. H. Andreas Flück, HR-Verantwortlicher, zukommen. Nähere Auskünfte erteilt Ihnen gern Prof. Dr. Gerhard Grundler, Institutsleiter, T +41 61 467 42 27.

[www.fhnw.ch](http://www.fhnw.ch)